Unlocking Mass Spec For Cell-Based Processes

Next Gen Process Analytical Technologies (PATs)

DynaPAT Platform

Introducing DynaPAT:

Platform-based Process Analytical Technologies (PATs) built for Modern Bioprocesses
DynaPAT Platform
Andson’s DynaPAT platform is a next generation sensor for the next generation of biotherapeutics.

The DynaPAT combines novel hardware solutions with advanced bioanalytics that together remove critical bottlenecks to discovering, developing and scaling Biologics, Advanced Therapies and other modern therapeutics - at every stage of development from lab to patient.

DynaPAT

Platform-based Process Analytical Technologies (PATs) Built for Modern Bioprocesses

Today

DynaCHIP

Learn More
1-Second Sample Prep
Exponentially Accelerated Mass Spec Workflows
Common Mass Spec Workflows
Piloting

DynaMARK

Learn More
Integrated Data Science Module
On-demand Assays with
Deeper Insight
Cell-Based Therapies Workflows
In Development

DynaLOOP

Learn More
In-Line Bioreactor Probe
Real-time Bioprocess
Monitoring and Control
Advanced Biomanufacturing

Our Pipeline

Our flagship product, the DynaCHIP, drops into existing mass spectrometry workflows to enable 1-second sample prep for exponentially faster results. On top of the DynaCHIP platform we are building the DynaMARK, which incorporates a data science module to generate on-demand measurements of the most important metrics for modern biopharma workflows. With the DynaLOOP we’re pioneering in-line cell-process monitoring and feedback control.

Our tools help drive down manufacturing costs, reduce drug development timelines and enable new drug processes by directly measuring what matters for these modern bioprocesses.

Our platform empowers Mass Spec to help you measure what matters, faster.

01

Accelerate and simplify "common" analytical measurements carried out by conventional mass spec workflows.

02

Develop better, faster assays to telescope the drug discovery process and get advanced therapies to market faster.

03

Provide predictive process control for reduced in-process failures of complex and costly biopharma processes.

Pilot Partnership

Contact Us

We're currently working with Pharma Co's and Biotechs to accelerate their Mass Spec workflows, and with Advanced Therapies Developers to enable better cell-state characterization.

If we can help accelerate your Mass Spec workflow or help measure critical biomarkers and cell-state for your iPSC and MSC research, please reach out!

Contact Us